Confronting The Challenges Of Marketing Cell And Gene Therapies
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.
You may also be interested in...
The norms on securing market access are being rewritten for cell and gene therapies.
The company will prioritize US market for gene therapies; FDA also placed eli-cel for CALD on clinical hold following a case of MDS.
Big changes are in store on the drug pricing front in Germany. Further reforms could depend on who is appointed health minister.